With the development of molecular sequencing technology and increasing research progress on the correlation between different molecules and the classification of gliomas, the identification of molecular information, such as CDKN2A/B co-deletion, EGFR amplification, TERT promoter mutations, and 1p/19q co-deletion, has allowed physicians to make a more accurate individual diagnosis and assessment of prognosis for patients (6). This evidence concerns the gene CDKN2A and glioma.